Home > Insider Trading > Filing (0001127602-12-023455)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
318154	Amgen Inc	AMGN	Biological Products, (No Disgnostic Substances) (2836)	953540776

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1491654	J.w. Thomas Dittrich	One Amgen Center Drive Thousand Oaks CA 91320	Vp, Finance & Cao	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2012-07-31	25,000	$69.83	38,721	No	4	M	Direct
Common Stock	Acquisiton	2012-07-31	3,000	$42.13	41,721	No	4	M	Direct
Common Stock	Acquisiton	2012-07-31	2,000	$50.44	43,721	No	4	M	Direct
Common Stock	Acquisiton	2012-07-31	2,150	$58.43	45,871	No	4	M	Direct
Common Stock	Disposition	2012-07-31	32,150	$82.69	13,721	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Nqso (Right to Buy)	Disposition	2012-07-31	25,000	$0.00	25,000	$69.83
Common Stock	Nqso (Right to Buy)	Disposition	2012-07-31	3,000	$0.00	3,000	$42.13
Common Stock	Nqso (Right to Buy)	Disposition	2012-07-31	2,000	$0.00	2,000	$50.44
Common Stock	Nqso (Right to Buy)	Disposition	2012-07-31	2,150	$0.00	2,150	$58.43

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2007-05-15	2013-05-15	No	4	M	Direct
0	2009-04-29	2015-04-29	No	4	M	Direct
2,000	2010-04-28	2016-04-28	No	4	M	Direct
4,300	2011-04-26	2020-04-26	No	4	M	Direct

Footnotes

The price reported is an average price. The prices ranged from $82.67 to $82.75 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer.
The shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 286 RSUs which fully vest on 4/28/2013; 615 RSUs which vest in annual installments of 307 on 4/26/2013 and 308 on 4/26/2014; 1,714 RSUs which vest in annual installments of 565, 566 and 583 on 4/25/2013, 4/25/2014 and 4/25/2015, respectively; and 1,400 RSUs which vest in two equal installments of 462 each on 4/27/2014 and 4/27/2015 and one installment of 476 on 4/27/2016. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
These shares include 7 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.